open access

Ahead of Print
Research paper
Published online: 2022-11-17
Get Citation

Practical application of modified ASCCP 2019 algorithms in the diagnosis and early detection of cervical pathology

Klaudyna Madziar1, Witold Kedzia1
DOI: 10.5603/GP.a2022.0092
·
Pubmed: 36448353
Affiliations
  1. Division of Gynecology, Department of Perinatology and Gynecology, Gynecology and Obstetrics Clinical Hospital, Karol Marcinkowski University of Medical Sciences, Poznan, Poland, Poland

open access

Ahead of Print
ORIGINAL PAPERS Gynecology
Published online: 2022-11-17

Abstract

Objectives: We assessed the risk for the high-grade precancerous CIN 2 (+) in women with HSIL and ASC-H depending on HPV status.

Material and methods: A retrospective analysis of results of cervical cancer screening following the current ASCCP recommendations by co-testing (LBC and molecular HPV DNA HR) performed between 2018 and 2022 in the Laboratory of Cervical Pathology, Obstetrics and Gynecology Hospital of Poznan University of Medical Sciences. Patient ages ranged from 22 to 72 years.

Results: The analysis of abnormal results of liquid-based cytology revealed the following: 1 suspicion of cervical carcinoma, 49 HSIL, 97 ASC-H, 95 LSIL, 92 ASCUS, and 4 AGC cases. Histopathological verification of the biopsy samples revealed a total of 288 abnormal results. CIN 2 (+) lesions were found in 127 women. ASC-H was the most common abnormal cytologic finding. Of the 338 molecular test results for HPV DNA HR, 85% were confirmed positive. A positive molecular signal confirming the presence of human papillomavirus on PAP smear was not homonymous with simultaneous histopathological diagnosis of cervical pathology.

Conclusions : There is a high risk for CIN 2 (+) in patients with HSIL and HPV 16 (+) and/or HPV DNA HR (+), as well as ASC-H and HPV 16 (+). HSIL is rarely observed in women with HPV 16 (–). The risk for CIN 2 (+) in women with ASC-H and HPV (–) is low.

Abstract

Objectives: We assessed the risk for the high-grade precancerous CIN 2 (+) in women with HSIL and ASC-H depending on HPV status.

Material and methods: A retrospective analysis of results of cervical cancer screening following the current ASCCP recommendations by co-testing (LBC and molecular HPV DNA HR) performed between 2018 and 2022 in the Laboratory of Cervical Pathology, Obstetrics and Gynecology Hospital of Poznan University of Medical Sciences. Patient ages ranged from 22 to 72 years.

Results: The analysis of abnormal results of liquid-based cytology revealed the following: 1 suspicion of cervical carcinoma, 49 HSIL, 97 ASC-H, 95 LSIL, 92 ASCUS, and 4 AGC cases. Histopathological verification of the biopsy samples revealed a total of 288 abnormal results. CIN 2 (+) lesions were found in 127 women. ASC-H was the most common abnormal cytologic finding. Of the 338 molecular test results for HPV DNA HR, 85% were confirmed positive. A positive molecular signal confirming the presence of human papillomavirus on PAP smear was not homonymous with simultaneous histopathological diagnosis of cervical pathology.

Conclusions : There is a high risk for CIN 2 (+) in patients with HSIL and HPV 16 (+) and/or HPV DNA HR (+), as well as ASC-H and HPV 16 (+). HSIL is rarely observed in women with HPV 16 (–). The risk for CIN 2 (+) in women with ASC-H and HPV (–) is low.

Get Citation

Keywords

cervical intraepithelial neoplasia; uterine cervical neoplasms

About this article
Title

Practical application of modified ASCCP 2019 algorithms in the diagnosis and early detection of cervical pathology

Journal

Ginekologia Polska

Issue

Ahead of Print

Article type

Research paper

Published online

2022-11-17

Page views

170

Article views/downloads

110

DOI

10.5603/GP.a2022.0092

Pubmed

36448353

Keywords

cervical intraepithelial neoplasia
uterine cervical neoplasms

Authors

Klaudyna Madziar
Witold Kedzia

References (11)
  1. International Agency for Research on Cancer – IARC, Globocan 2020. Estimated cancer inci-dence, mortality and prevalence worldwide 2020. http://globocan.iarc.fr (14.04.2022).
  2. Dankai W, Khunamornpong S, Siriaunkgul S, et al. Role of genomic DNA methylation in detection of cytologic and histologic abnormalities in high risk HPV-infected women. PLoS One. 2019; 14(1): e0210289.
  3. International Agency for Research on Cancer – IARC, Globocan 2020. Estimated cancer inci-dence, mortality and prevalence in Poland 2020. https://gco.iarc.fr/today/data/factsheets/populations/616-poland-fact-sheets.pdf (16.08.2022).
  4. Habbema D, De Kok IM, Brown ML. Cervical cancer screening in the United States and the Netherlands: a tale of two countries. Milbank Q. 2012; 90(1): 5–37.
  5. ASCCP. https://www.asccp.org/management-guidelines (01.03.2022).
  6. Perkins RB, Guido RS, Castle PE, et al. ASCCP Risk-Based Management Consensus Guidelines Committee 2019. ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Journal of Lower Genital Tract Disease. 2020; 24(2): 102–131.
  7. https://diag.pl/wp-content/uploads/sites/3/2016/11/HPV_DNA_HR_2016.pdf (22.06.2022).
  8. Jach R, Mazurec M, Trzeszcz M, et al. Cervical cancer screening in Poland in current SARS-CoV-2 pandemic: Interim guidelines of the Polish Society of Gynecologists and Obstetricians and the Polish Society of Colposcopy and Cervical Pathophysiology - a summary January 2021. Ginekol Pol. 2021; 92(2): 165–173.
  9. Kaban I, Bacanakgil BH, Koca S. The comparison of two methods in cervical smear screening - which method is better for smear adequacy rates? Ginekol Pol. 2021; 92(5): 335–338.
  10. PQStat Software. https://pqstat.pl/kontakt (01.03.2022).
  11. Keskin N, Biyik I, Ince O, et al. Evaluation of the consistency ratios of cervical smear, cervical biopsy and conization results. Ginekol Pol. 2021; 92(11): 778–783.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl